Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents

An emerging entity with a poor prognosis

Elias Jabbour, Hady Ghanem, Xuelin Huang, Farhad Ravandi, Guillermo Garcia-Manero, Susan O'brien, Stephan Faderl, Sherry Pierce, Sangbum Choi, Srdan Verstovsek, Mark Brandt, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalComment/debate

8 Citations (Scopus)

Abstract

We assessed the outcomes of 63 patients with acute myeloid leukemia (AML) arising from myelodysplastic syndrome (MDS) after hypomethylating agent failure. Their median age was 63 years. All 63 patients had received ≥ 1 salvage regimens for AML, and 35 patients (55%) had received ≥ 2. Of the 31 patients (49%) who had received high-dose cytarabine (HDAC) at first relapse, 2 (6%) achieved complete remission (CR) and 4 (13%) CR with incomplete platelet recovery (overall response rate, 19%). Of the 32 patients (51%) who had received other treatments, including investigational agents, 4 (12%) achieved CR and 4 (12%) CR with incomplete platelet recovery (overall response rate, 24%). The median response duration was 20 weeks. With a median follow-up of 42 months from the AML diagnosis, the median survival (21 weeks) was similar between the 2 groups. The 1- and 2-year survival rate was 19% and 8%, respectively. Multivariate analysis identified low albumin, HDAC treatment, and platelet count < 50 × 109/L as independent adverse factors for CR and a platelet count < 50 × 109/L and age > 65 years as independent adverse factors for survival. Thus, the outcome of AML evolving from MDS after hypomethylating agent failure is poor and not improved with HDAC. Novel therapies directed toward this emerging entity are urgently needed.

Original languageEnglish
Pages (from-to)93-97
Number of pages5
JournalClinical Lymphoma, Myeloma and Leukemia
Volume14
Issue number2
DOIs
Publication statusPublished - 2014 Jan 1
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Acute Myeloid Leukemia
Blood Platelets
Therapeutics
Investigational Therapies
Survival
Cytarabine
Platelet Count
Albumins
Multivariate Analysis
Survival Rate
Recurrence

Keywords

  • Acute myeloid leukemia
  • Hypomethylating agent failure
  • Myelodysplastic syndromes
  • Outcomes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents : An emerging entity with a poor prognosis. / Jabbour, Elias; Ghanem, Hady; Huang, Xuelin; Ravandi, Farhad; Garcia-Manero, Guillermo; O'brien, Susan; Faderl, Stephan; Pierce, Sherry; Choi, Sangbum; Verstovsek, Srdan; Brandt, Mark; Cortes, Jorge; Kantarjian, Hagop.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 14, No. 2, 01.01.2014, p. 93-97.

Research output: Contribution to journalComment/debate

Jabbour, E, Ghanem, H, Huang, X, Ravandi, F, Garcia-Manero, G, O'brien, S, Faderl, S, Pierce, S, Choi, S, Verstovsek, S, Brandt, M, Cortes, J & Kantarjian, H 2014, 'Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: An emerging entity with a poor prognosis', Clinical Lymphoma, Myeloma and Leukemia, vol. 14, no. 2, pp. 93-97. https://doi.org/10.1016/j.clml.2013.10.013
Jabbour, Elias ; Ghanem, Hady ; Huang, Xuelin ; Ravandi, Farhad ; Garcia-Manero, Guillermo ; O'brien, Susan ; Faderl, Stephan ; Pierce, Sherry ; Choi, Sangbum ; Verstovsek, Srdan ; Brandt, Mark ; Cortes, Jorge ; Kantarjian, Hagop. / Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents : An emerging entity with a poor prognosis. In: Clinical Lymphoma, Myeloma and Leukemia. 2014 ; Vol. 14, No. 2. pp. 93-97.
@article{e52ff4fa644c473e8fcdd2144909aa25,
title = "Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: An emerging entity with a poor prognosis",
abstract = "We assessed the outcomes of 63 patients with acute myeloid leukemia (AML) arising from myelodysplastic syndrome (MDS) after hypomethylating agent failure. Their median age was 63 years. All 63 patients had received ≥ 1 salvage regimens for AML, and 35 patients (55{\%}) had received ≥ 2. Of the 31 patients (49{\%}) who had received high-dose cytarabine (HDAC) at first relapse, 2 (6{\%}) achieved complete remission (CR) and 4 (13{\%}) CR with incomplete platelet recovery (overall response rate, 19{\%}). Of the 32 patients (51{\%}) who had received other treatments, including investigational agents, 4 (12{\%}) achieved CR and 4 (12{\%}) CR with incomplete platelet recovery (overall response rate, 24{\%}). The median response duration was 20 weeks. With a median follow-up of 42 months from the AML diagnosis, the median survival (21 weeks) was similar between the 2 groups. The 1- and 2-year survival rate was 19{\%} and 8{\%}, respectively. Multivariate analysis identified low albumin, HDAC treatment, and platelet count < 50 × 109/L as independent adverse factors for CR and a platelet count < 50 × 109/L and age > 65 years as independent adverse factors for survival. Thus, the outcome of AML evolving from MDS after hypomethylating agent failure is poor and not improved with HDAC. Novel therapies directed toward this emerging entity are urgently needed.",
keywords = "Acute myeloid leukemia, Hypomethylating agent failure, Myelodysplastic syndromes, Outcomes",
author = "Elias Jabbour and Hady Ghanem and Xuelin Huang and Farhad Ravandi and Guillermo Garcia-Manero and Susan O'brien and Stephan Faderl and Sherry Pierce and Sangbum Choi and Srdan Verstovsek and Mark Brandt and Jorge Cortes and Hagop Kantarjian",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.clml.2013.10.013",
language = "English",
volume = "14",
pages = "93--97",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "2",

}

TY - JOUR

T1 - Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents

T2 - An emerging entity with a poor prognosis

AU - Jabbour, Elias

AU - Ghanem, Hady

AU - Huang, Xuelin

AU - Ravandi, Farhad

AU - Garcia-Manero, Guillermo

AU - O'brien, Susan

AU - Faderl, Stephan

AU - Pierce, Sherry

AU - Choi, Sangbum

AU - Verstovsek, Srdan

AU - Brandt, Mark

AU - Cortes, Jorge

AU - Kantarjian, Hagop

PY - 2014/1/1

Y1 - 2014/1/1

N2 - We assessed the outcomes of 63 patients with acute myeloid leukemia (AML) arising from myelodysplastic syndrome (MDS) after hypomethylating agent failure. Their median age was 63 years. All 63 patients had received ≥ 1 salvage regimens for AML, and 35 patients (55%) had received ≥ 2. Of the 31 patients (49%) who had received high-dose cytarabine (HDAC) at first relapse, 2 (6%) achieved complete remission (CR) and 4 (13%) CR with incomplete platelet recovery (overall response rate, 19%). Of the 32 patients (51%) who had received other treatments, including investigational agents, 4 (12%) achieved CR and 4 (12%) CR with incomplete platelet recovery (overall response rate, 24%). The median response duration was 20 weeks. With a median follow-up of 42 months from the AML diagnosis, the median survival (21 weeks) was similar between the 2 groups. The 1- and 2-year survival rate was 19% and 8%, respectively. Multivariate analysis identified low albumin, HDAC treatment, and platelet count < 50 × 109/L as independent adverse factors for CR and a platelet count < 50 × 109/L and age > 65 years as independent adverse factors for survival. Thus, the outcome of AML evolving from MDS after hypomethylating agent failure is poor and not improved with HDAC. Novel therapies directed toward this emerging entity are urgently needed.

AB - We assessed the outcomes of 63 patients with acute myeloid leukemia (AML) arising from myelodysplastic syndrome (MDS) after hypomethylating agent failure. Their median age was 63 years. All 63 patients had received ≥ 1 salvage regimens for AML, and 35 patients (55%) had received ≥ 2. Of the 31 patients (49%) who had received high-dose cytarabine (HDAC) at first relapse, 2 (6%) achieved complete remission (CR) and 4 (13%) CR with incomplete platelet recovery (overall response rate, 19%). Of the 32 patients (51%) who had received other treatments, including investigational agents, 4 (12%) achieved CR and 4 (12%) CR with incomplete platelet recovery (overall response rate, 24%). The median response duration was 20 weeks. With a median follow-up of 42 months from the AML diagnosis, the median survival (21 weeks) was similar between the 2 groups. The 1- and 2-year survival rate was 19% and 8%, respectively. Multivariate analysis identified low albumin, HDAC treatment, and platelet count < 50 × 109/L as independent adverse factors for CR and a platelet count < 50 × 109/L and age > 65 years as independent adverse factors for survival. Thus, the outcome of AML evolving from MDS after hypomethylating agent failure is poor and not improved with HDAC. Novel therapies directed toward this emerging entity are urgently needed.

KW - Acute myeloid leukemia

KW - Hypomethylating agent failure

KW - Myelodysplastic syndromes

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=84896400624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896400624&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2013.10.013

DO - 10.1016/j.clml.2013.10.013

M3 - Comment/debate

VL - 14

SP - 93

EP - 97

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 2

ER -